I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Belgium

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience EAN 2023
Roche and Genentech at

EAN 2023

July 01 - July 04
Budapest, Hungary
ean.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Jul 3 / Roche and Genentech
ILLUMINATE: A Real-World Study Assessing Usability and Value of Integrated Digital Tools for MS care
A study design report for the ILLUMINATE study, a non-interventional proof-of-concept study assessing the usability and value of a digital MS care management platform in medical practice. The ILLUMINATE study design, rationale and aim, study objectives and their corresponding endpoints are presented.
Neuroscience Multiple Sclerosis EAN-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jul 2 / Roche and Genentech
Attitudes toward seeking professional help among patients with early alzheimer´s disease
An earlier diagnosis of Alzheimer's disease (AD) allows patients and their families to be better informed to make decisions and plan their lives, benefit from pharmacological and non-pharmacological strategies, and have the possibility to participate in clinical trials of new diseasemodifying agents. Knowledge of the active process of seeking professional help in the early stages of AD and its associated factors is still limited. The aim of this study was to assess the phenomenon.
Neuroscience Alzheimer Disease EAN-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jul 2 / Roche and Genentech
Efficacy and Safety of Fenebrutinib, a Noncovalent, Reversible BTK inhibitor, in MS: Primary Results of a Phase 2 Trial
Bruton’s tyrosine kinase (BTK) is implicated in peripheral and central nervous system inflammation in multiple sclerosis (MS) and is a therapeutic target for relapsing and progressive disease. Fenebrutinib is a potent, highly selective, noncovalent, reversible BTK inhibitor under investigation for MS. The objective of FENopta, a randomized, double-blind, placebo-controlled, Phase 2 trial (NCT05119569), was to evaluate efficacy and safety of fenebrutinib in relapsing MS.
Neuroscience Multiple Sclerosis EAN-2023
02:00 PM
Duration 5mins ePoster area
FIREFISH Parts 1 and 2: 48-month efficacy and safety of risdiplam▼ in Type 1 spinal muscular atrophy (SMA)
M Mazurkiewicz-Beldzinska, G Baranello, O Boespflug-Tanguy, JW Day, N Deconinck, A Klein, R Masson, E Mercuri, K Rose, L Servais, D Vlodavets, H Xiong, E Zanoteli, M El-Khairi, M Gerber, K Gorni, H Kletzl, L Palfreeman, A Dodman, BT Darras
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 5mins ePoster area
SUNFISH Parts 1 and 2: 4-year efficacy and safety data of risdiplam▼ in Types 2 and 3 spinal muscular atrophy (SMA)
A Kostera-Pruszczyk, JW Day, N Deconinck, ES Mazzone, A Nascimento, M Oskoui, K Saito, C Vuillerot, G Baranello, O Boespflug-Tanguy, N Goemans, J Kirschner, L Servais, J Braid, M Gerber, K Gorni, C Martin, WY Yeung, RS Scalco, E Mercuri
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.